Skip to content
Catalyst

PapersPMID:39267574

Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study.

Cancer medicine2024The record ↗

  1. Finding, moderate evidenceraisesProgression-free survival

What moved

1 findingHow to read these marks →
  • “Compared with the control group, the 6‐ and 12‐month PFS rates were significantly higher in the inosine group (Table 2).”
    Study
    RCT
    Dose studied
    inosine tablets, 0.2 g three times daily, added to PD-1/PD-L1 inhibitor regimen until progression or unacceptable toxicity
    Population
    Adults aged 18-75 with advanced (locally advanced, recurrent, metastatic or unresectable) malignant solid tumours receiving PD-1/PD-L1 inhibitor therapy, with or without targeted therapy or chemotherapy, in both arms; PFS rates at the 6- and 12-month landmarks

Study record

Design
randomised controlled trial
Species
human
Population
patients with advanced malignant solid tumors receiving PD-1/PD-L1 inhibitor therapy
Participants
172
Comparator
no treatment
Duration
not reported
Endpoints measured
74